Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Flexor Tendon Tenotomy Treatment of the Diabetic Foot: A Multicenter Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Symptoms reported in calls to emergency medical services within 24 hours prior to out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiac Rehabilitation for Patients with Heart failure: Association With Readmission and Mortality Risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Hertzel C Gerstein
  • Sibylle Hess
  • Brian Claggett
  • Kenneth Dickstein
  • Lars Kober
  • Aldo P Maggioni
  • John J V McMurray
  • Jeffrey L Probstfield
  • Matthew C Riddle
  • Jean-Claude Tardif
  • Marc A Pfeffer
Vis graf over relationer

OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death.

RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel.

RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively.

CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP's prognostic value.

OriginalsprogEngelsk
TidsskriftDiabetes Care
Vol/bind45
Udgave nummer9
Sider (fra-til)2152-2155
Antal sider4
ISSN1935-5548
DOI
StatusUdgivet - 1 sep. 2022

Bibliografisk note

© 2022 by the American Diabetes Association.

ID: 79301950